Arsenal Vascular

Arsenal Medical is a pioneering platform technology company specializing in the development of novel, therapeutic in situ forming materials. The company's core product is a system that injects an elastomeric polymer material to fill and seal aneurysm sacs around stent grafts. This material flows around the graft and cures into an elastic solid, effectively sealing off branch vessels to prevent aneurysm expansion, enhancing graft seals to minimize endoleaks, and stabilizing graft position to prevent migration.

Founded by George Whitesides and Robert Langer, Arsenal Medical operates in the medical device and biotechnology sectors. The company primarily serves healthcare providers and medical institutions that treat patients with aneurysms. Arsenal Medical's business model revolves around the development and commercialization of its proprietary polymer technology, which has received investigational device exemption approval from the U.S. FDA for clinical studies.

Revenue is generated through the sale of its medical devices and potentially through licensing agreements for its technology. The company also spun out Lyra Therapeutics in 2011 to advance a clinical-stage drug delivery system that provides a steady dose of medication directly to diseased tissues.

Keywords: in situ curing, elastomeric polymer, aneurysm treatment, stent graft, medical device, biotechnology, FDA approval, therapeutic materials, healthcare providers, drug delivery system.